crenezumab

Crenezumab is a fully humanized monoclonal antibody developed as a passive immunotherapy for Alzheimer's disease. It targets multiple forms of beta-amyloid (Aβ) peptides, including oligomeric and fibrillar species with high affinity and monomeric Aβ with lower affinity. Crenezumab uses an IgG4 backbone to reduce effector function on microglia, aiming to stimulate amyloid phagocytosis while minimizing inflammatory side effects such as vasogenic edema. The drug was designed to neutralize neurotoxic oligomers of beta-amyloid, inhibit aggregation, promote disaggregation of existing plaques, and block the interaction between Aβ oligomers and neurons. Crenezumab was discovered by AC Immune using its SupraAntigen technology and later licensed to Genentech for clinical development and commercialization[1][3][4][5].

Other names

crenezumab